gip glp 1 agonists Understand GLP-1/GIP Dual Agonist Tirzepatide and Its Effect on Current Weight Loss Therapy Frontiers | Clinical perspectives on
Description
Industry Size (2026): USD 2.9 Bn Forecast (2036): USD 7.8 Bn CAGR (2026 to 2036): 11.7% GLP-1 Receptor Agonist Market Size, Market Forecast and Outlook By FMI The GLP-1 receptor agonist market is expected to expand from USD 2.9 billion in 2026 to USD 7.8 billion by 2036
Even then, close gastroenterologist oversight and frequent monitoring are essential throughout treatment
10.1016/j.bbrc.2017.06.031
Innovator Novo Nordisk launched its semaglutide brands Wegovy and Ozempic in India last year, racing to capture early market share before losing patent exclusivity on 20 March 2026
90.Heerspink HJL, Stefansson BV, Correa-Rotter R, et al
S., Hafermann, J
